ArriVent BioPharma, Inc Common Stock

Yahoo Finance • 24 days ago

ArriVent Biopharma, Inc. Full Year Loss Increases

(RTTNews) - ArriVent Biopharma, Inc. (AVBP) reported Loss for its full year of -$166.31 million The company's bottom line totaled -$166.31 million, or -$4.32 per share. This compares with -$80.49 million, or -$2.56 per share, last year.... Full story

Yahoo Finance • 3 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regul... Full story

Yahoo Finance • 6 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics... Full story

Yahoo Finance • 8 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1 Study for ARR-217 (MRG... Full story

Yahoo Finance • 8 months ago

ArriVent expects topline data from lung cancer drug trial in early 2026

NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical company with a market capitalization of $805 million, announced Monday that topline data from its global pivotal Phase 3 FURVENT study of firm... Full story

Yahoo Finance • 9 months ago

ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval

Investing.com - Clear Street has reiterated its Buy rating and $32.00 price target on ArriVent BioPharma (NASDAQ:AVBP), currently trading at $21.1, following the July 2 approval of competitor drug sunvozertinib (ZEGFROVY) for second-line E... Full story

Yahoo Finance • 9 months ago

ArriVent BioPharma prices $75M equity offering

ArriVent BioPharma (NASDAQ:AVBP [https://seekingalpha.com/symbol/AVBP]) has priced [https://seekingalpha.com/pr/20154385-arrivent-announces-pricing-of-75-million-public-offering-of-common-stock-and-pre-funded]a securities offering to raise... Full story

Yahoo Finance • 9 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today an... Full story

Yahoo Finance • 9 months ago

ArriVent BioPharma announces $75 million public offering

NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical company with a market capitalization of approximately $745 million, announced Tuesday its intention to offer $75 million of common stock and p... Full story

Yahoo Finance • 9 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today an... Full story

Yahoo Finance • 9 months ago

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright on strong NSCLC trial data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $40.00 price target on ArriVent BioPharma (NASDAQ:AVBP) following updated results from the company’s Phase 1b FURTHER trial evaluating firmonertinib in first-line EGFR PACC-po... Full story

Yahoo Finance • 9 months ago

Clear Street initiates ArriVent BioPharma stock with Buy rating

Investing.com - Clear Street initiated coverage on ArriVent BioPharma (NASDAQ:AVBP), which recently completed its IPO in January 2024, with a Buy rating and a $32.00 price target on Tuesday. The research firm cited firmonertinib, ArriVent... Full story

Yahoo Finance • 9 months ago

ArriVent reports 16-month progression-free survival for lung cancer drug

NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biotech company with a market capitalization of $863 million, announced follow-up data from its Phase 1b FURTHER trial showing 16.0 months median progression-fr... Full story

Yahoo Finance • 9 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) an... Full story

Yahoo Finance • 9 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,... Full story

Yahoo Finance • last year

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H 2025Expands ArriVent’s growin... Full story